Who makes Metformin hydrochlorid?

Metformin hydrochlorid is developed by Boehringer Ingelheim.

What development phase is Metformin hydrochlorid in?

Metformin hydrochlorid is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Metformin hydrochlorid

Boehringer Ingelheim · FDA-approved active Small molecule Quality 0/100

Metformin hydrochloride, marketed by Boehringer Ingelheim, is a well-established drug in the diabetes treatment market. A key strength is its strong market presence, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiry approaches.

At a glance

Generic name	Metformin hydrochlorid
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Metformin hydrochlorid CI brief — competitive landscape report
Metformin hydrochlorid updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI